ss - 31
the mitochondrial repair expert
overview
Think of your mitochondria like a high-performance engine. Over time, or due to disease, the fuel lines get brittle and start leaking.
The Problem: Most supplements are like "fire extinguishers"—they put out the sparks (oxidative stress) caused by the leaks, but they don't fix the engine itself.
The SS-31 Solution: This peptide acts like high-grade sealant. It binds to a specific lipid (cardiolipin) that holds the engine together. By stabilizing this structure, it stops the leaks, boosts fuel efficiency (ATP production), and prevents the engine from overheating and burning out.
FDA Breakthrough (Late 2025): In a historic win for mitochondrial medicine, the FDA granted accelerated approval to Elamipretide (brand name Forzinity) in September 2025 for Barth syndrome. This is the first-ever FDA-approved drug specifically designed to target and repair mitochondrial membranes.
Commercial Launch (2026): As of early 2026, the drug is officially hitting the U.S. market. While its current approval is for a rare genetic condition, the medical community is closely watching its "off-label" potential for anti-aging, heart failure, and neurodegenerative diseases like Parkinson’s.
Clinical Expansion: Stealth BioTherapeutics is currently pushing Phase 3 trials (ReNEW) for Dry Age-Related Macular Degeneration (AMD), with data expected by 2027, signaling its move from "rare disease fix" to "mainstream longevity tool."